We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Magnetically Levitated Rotor Helps Heart Pump Blood

By HospiMedica International staff writers
Posted on 24 Sep 2008
A new left ventricle assist system (LVAS) levitates in the middle of the heart chamber, never touching the walls, consistently pushing blood from the heart to the body.

The DuraHeart LVAS is a third-generation rotary blood pump designed for long-term patient support. More...
It incorporates a centrifugal flow rotary pump with a magnetically levitated impeller to pump blood from the heart around the body. The magnetically levitating impeller--shaped like a flat magnetic disc the size of hockey puck--acts as a paddlewheel, turning constantly as it is suspended in a magnetic field coupled to a turning motor within the pump housing. This expels the blood into a flexible artificial blood vessel, called the outflow conduit, which is connected to the ascending aorta. As a result, the DuraHeart may cause less damage to blood cells and be less likely to allow dangerous blood clots to form, compared with other heart-assisting devices that use mechanical pumps. During the implantation procedure, the surgeon diverts blood flow from the ailing left ventricle of the heart into a titanium tube that leads into the pumping chamber. The DuraHeart a product of Terumo Heart (Ann Arbor, MI, USA), has received the European Community (EC) marking, and is currently undergoing clinical trails in the United Sates.

"This trial will test the DuraHeart's potential to overcome some of the issues that have been seen with other devices, including hemolysis caused by shear stress on red blood cells, and clotting risk caused by blood that does not circulate rapidly enough from all areas of the chamber,” said surgeon Francis Pagani, M.D., Ph.D. of the University of Michigan (Ann Arbor, MI, USA) cardiovascular center, who is co-leader of the U.S. clinical trial of the DuraHeart. "It also remains to be seen if this device offers superior durability, which might make it useful as a destination therapy that could remove the need for a heart transplant.”

Related Links:
Terumo Heart
University of Michigan



Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Desk Aneroid Sphyg
Diagnostix 750D+
New
Monitor/Defibrillator
Zenix
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Health IT

view channel
Photo courtesy of Adobe Stock

Automated System Classifies and Tracks Cardiogenic Shock Across Hospital Settings

Cardiogenic shock remains a difficult, time-sensitive emergency, with delayed identification driving poor outcomes and persistently high mortality. Many cases go undocumented even at advanced stages, hindering... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.